RAPT Therapeutics, Inc. (RAPT) Total Liabilities (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Total Liabilities for 5 consecutive years, with $13.0 million as the latest value for Q3 2024.
- Quarterly Total Liabilities fell 51.86% to $13.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Sep 2024, down 51.86% year-over-year, with the annual reading at $26.3 million for FY2023, 24.95% up from the prior year.
- Total Liabilities hit $13.0 million in Q3 2024 for RAPT Therapeutics, down from $18.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $27.9 million in Q1 2023 to a low of $12.3 million in Q4 2021.
- Historically, Total Liabilities has averaged $19.2 million across 5 years, with a median of $19.0 million in 2020.
- Biggest five-year swings in Total Liabilities: skyrocketed 71.7% in 2022 and later tumbled 51.86% in 2024.
- Year by year, Total Liabilities stood at $14.8 million in 2020, then dropped by 17.13% to $12.3 million in 2021, then skyrocketed by 71.7% to $21.0 million in 2022, then rose by 24.95% to $26.3 million in 2023, then plummeted by 50.71% to $13.0 million in 2024.
- Business Quant data shows Total Liabilities for RAPT at $13.0 million in Q3 2024, $18.0 million in Q2 2024, and $25.0 million in Q1 2024.